Diabetology & metabolic syndrome

Effectiveness and safety of orforglipron for obesity with type 2 diabetes: a combined analysis of clinical trials

Updated

Abstract

In a meta-analysis of three randomized controlled trials involving 2,505 participants, orforglipron demonstrated reductions in body weight of up to 7.80% compared to placebo.

  • Weight reductions ranged from 2.43% at a 3 mg dose to 7.80% at a 24 mg dose.
  • Body mass index (BMI) reductions varied from 0.88 kg/m² at 3 mg to 2.70 kg/m² at 45 mg.
  • Significant waist circumference reductions were noted at doses of 6 mg or higher, reaching 5.90 cm at 24 mg.
  • Glycated hemoglobin (HbA1c) levels decreased by 0.80% at 3 mg and 1.67% at 45 mg.
  • Fasting serum glucose levels declined from 20.62 mg/dL at 3 mg to 44.80 mg/dL at 45 mg.
  • Increased treatment discontinuation due to adverse events was observed with orforglipron, but serious adverse events were not significantly different from placebo.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declarations. Ethics approval and consent to participate: Not applicable. AI use: The authors confirm that no artificial intelligence was used. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free